Ilya Noginskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilya Noginskiy has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Angelica Singh
New York Presbyterian Brooklyn Methodist Hospital—Weill Cornell Medical College, Brooklyn, NY 11215, USA
1 shared publication - Marina Barsoum
New York Presbyterian Brooklyn Methodist Hospital—Weill Cornell Medical College, Brooklyn, NY 11215, USA
1 shared publication - Soeb Usta
New York Presbyterian Brooklyn Methodist Hospital—Weill Cornell Medical College, Brooklyn, NY 11215, USA
1 shared publication - Sofia Zahid
New York Presbyterian Brooklyn Methodist Hospital—Weill Cornell Medical College, Brooklyn, NY 11215, USA
1 shared publication - Timothy Pak
New York Presbyterian Brooklyn Methodist Hospital—Weill Cornell Medical College, Brooklyn, NY 11215, USA
1 shared publication - Uqba Khan
Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, 1305 York Avenue, Room Y1247, New York, NY 10021, USA
1 shared publication
Latest Publications
- Open Access
- 8 September 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (9) , 6445-6462
A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many patients are diagnosed in the advanced stages precluding them from locoregional therapy. Therapeutic agents for advanced hepatocellular carcinoma were limited to Sorafenib for several years; however, with the emergence of molecular targeted therapies including tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, in addition to immunotherapies, the way hepatocellular carcinoma is treated has changed significantly. In this review, we summarize the key clinical trials that lead to the approval of these agents for systemic treatment of hepatocellular carcinoma and discuss the preferred sequence of treatment options as well as prospective studies for management of hepatocellular carcinoma.
- 8 September 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (9) , 6445-6462
Open AccessA Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many patients are diagnosed in the advanced stages precluding them from locoregional therapy. Therapeutic agents for advanced hepatocellular carcinoma were limited to Sorafenib for several years; however, with the emergence of molecular targeted therapies including tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors, in addition to immunotherapies, the way hepatocellular carcinoma is treated has changed significantly. In this review, we summarize the key clinical trials that lead to the approval of these agents for systemic treatment of hepatocellular carcinoma and discuss the preferred sequence of treatment options as well as prospective studies for management of hepatocellular carcinoma.